Verona Pharma initiated with a Buy at Roth MKM
Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its ...
Verona Pharma’s Ohtuvayre: Unique COPD Solution Drives Buy Rating Amid Market Potential and Revenue Growth
Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...